ADMA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
141.1M
+13.4%
124.4M
+8.6%
114.5M
-17.7%
139.2M
+3.7%
134.2M
Cost of Revenue
41.2M
+8.2%
38.1M
+13.0%
33.7M
-33.0%
50.3M
-14.1%
58.6M
Gross Profit
99.9M
+15.7%
86.3M
+6.8%
80.8M
-9.1%
88.8M
+17.5%
75.6M
Operating Expenses
32.1M
-5.1%
33.8M
+11.1%
30.5M
+16.8%
26.1M
+6.1%
24.6M
R&D
4.5M
-25.3%
6.0M
+131.6%
2.6M
+88.7%
1.4M
-9.9%
1.5M
SG&A
26.6M
-0.7%
26.7M
-0.0%
26.7M
+13.7%
23.5M
+8.0%
21.8M
Operating Income
67.8M
+29.2%
52.4M
+4.3%
50.3M
-19.9%
62.8M
+23.0%
51.0M
EBITDA
69.5M
+28.3%
54.2M
+4.0%
52.1M
-19.5%
64.8M
+22.2%
53.0M
Net Income
49.9M
+31.9%
37.8M
-16.6%
45.3M
-8.2%
49.4M
+35.6%
36.4M
EPS (Basic)
$0.22
+29.4%
$0.17
-10.5%
$0.19
-9.5%
$0.21
+40.0%
$0.15
EPS (Diluted)
$0.22
+37.5%
$0.16
-15.8%
$0.19
-5.0%
$0.20
+33.3%
$0.15
Shares (Diluted)
225.8M
-2.0%
230.3M
-4.0%
240.0M
-0.7%
241.7M
-1.2%
244.7M
ADMA Biologics (ADMA) — Financials